Although rare, the deletion of the long arm of Chr 9 (del9q) is considered as an intermediate risk factor for AML, and is characterized by frequent mutations of DNMT3A, WT1, and NPM1 genes (Dohner et al., 2010; Herold et al., 2017). This evidence concerns the gene DNMT3A and acute myeloid leukemia.